NVAX · Company research
Novavax Inc (NVAX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors | Novavax stock declined 3.91% to $10.82, underperforming the broader market's gains. While the vaccine maker gained 11.38% over the past month, upcoming earnings expectations show challenges ahead with anticipated EPS of -$0.33 and revenue declining 28.15% year-over-year. The company holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bearish | -1 | 1 |
| Discipline and Rules-Based Execution in NVAX Response - Stock Traders Daily | Discipline and Rules-Based Execution in NVAX Response Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 16, 2026 | neutral | 0 | 0.6 |
| NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open - Stocktwits | NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know | Novavax stock closed at $12.82, up 1.26% and outperforming the broader market decline. The vaccine maker has surged 32.01% over the past month. However, upcoming earnings show mixed signals: EPS expected to improve 46.77% YoY to -$0.33, but revenue projected to fall 28.15% to $50.61 million. Full-year estimates show significant declines with -114.73% EPS change and -66.4% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals - Stocktwits | NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Dow, S&P 500, Nasdaq Futures Edge Higher After Nasdaq Climbs To Record High: SPCX, USAR, CEG, NVAX Stocks In Focus - Stocktwits | Dow, S&P 500, Nasdaq Futures Edge Higher After Nasdaq Climbs To Record High: SPCX, USAR, CEG, NVAX Stocks In Focus Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits | NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| NOVAVAX INC (NVAX) Stock Chart - ChartMill | NOVAVAX INC (NVAX) Stock Chart ChartMill | View source ↗ | ChartMill | Oct 10, 2026 | neutral | 0 | 0.6 |
| NVAX Stock Grinds Higher As Traders Watch Volatile Rebound - Timothy Sykes | NVAX Stock Grinds Higher As Traders Watch Volatile Rebound Timothy Sykes | View source ↗ | Timothy Sykes | Oct 9, 2026 | neutral | 0 | 0.6 |
| Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know | Novavax has recently attracted investor attention with shares returning +18.4% over the past month, outperforming the S&P 500. However, the company faces significant headwinds including a projected loss of $0.38 per share for the current quarter and declining revenues expected to fall 66.4% for the current fiscal year. The stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know | Novavax has recently attracted investor attention with shares returning +18.4% over the past month, outperforming the S&P 500. However, the company faces significant headwinds including a projected loss of $0.38 per share for the current quarter and declining revenues expected to fall 66.4% for the current fiscal year. The stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance | Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade - Yahoo Finance | Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Novavax (NVAX) Stock Sinks As Market Gains: Here's Why | Novavax (NVAX) closed down 10.31% in recent trading. The vaccine maker faces headwinds with projected quarterly EPS of -$0.37 and revenue expected to decline 39.01% year-over-year to $42.96 million. Full-year estimates show -$0.46 EPS and $357.88 million revenue, representing significant declines. The stock holds a Zacks Rank #4 (Sell) rating with no recent changes to consensus estimates. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bearish | -1 | 1 |
| Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance | Novavax (NVAX) Stock Sinks As Market Gains: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? | Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.667 | 1 |
| Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? | Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.667 | 1 |
| Novavax (NVAX) Stock Looks Fully Priced On Its Current Sales Base - Simply Wall Street | Novavax (NVAX) Stock Looks Fully Priced On Its Current Sales Base Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test - Yahoo Finance | NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| Novavax jumps as investors revisit multi-market vaccine approvals and royalty upside - Quiver Quantitative | Novavax jumps as investors revisit multi-market vaccine approvals and royalty upside Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up - 24/7 Wall St. | Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 5, 2026 | neutral | 0 | 0.6 |
| Why is Novavax stock surging today? - Investing.com | Why is Novavax stock surging today? Investing.com | View source ↗ | Investing.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| Novavax Shorts on Edge as Russia Plague Fears Spread - Benzinga | Novavax Shorts on Edge as Russia Plague Fears Spread Benzinga | View source ↗ | Benzinga | Oct 5, 2026 | neutral | 0 | 0.6 |
| Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Eastern Progress | Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It Eastern Progress | View source ↗ | Eastern Progress | Sep 18, 2026 | neutral | 0 | 0.6 |
| Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock? - Yahoo Finance | Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 18, 2026 | neutral | 0 | 0.6 |
| Novavax's protein-based COVID vaccine gets approvals in the U.S., EU and Japan - Stock Titan | Novavax's protein-based COVID vaccine gets approvals in the U.S., EU and Japan Stock Titan | View source ↗ | Stock Titan | Aug 28, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.